These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35062716)

  • 1. COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional Study.
    Shehab M; Zurba Y; Al Abdulsalam A; Alfadhli A; Elouali S
    Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 Vaccine Booster Dose Willingness among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study.
    Shehab M; Alrashed F; Alfadhli A
    Vaccines (Basel); 2022 Jul; 10(8):. PubMed ID: 35893815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies.
    Shehab M; Alrashed F; Alfadhli A; Alotaibi K; Alsahli A; Mohammad H; Cherian P; Al-Khairi I; Alphonse Thanaraj T; Channanath A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
    Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960217
    [No Abstract]   [Full Text] [Related]  

  • 4. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
    Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
    Kennedy NA; Lin S; Goodhand JR; Chanchlani N; Hamilton B; Bewshea C; Nice R; Chee D; Cummings JF; Fraser A; Irving PM; Kamperidis N; Kok KB; Lamb CA; Macdonald J; Mehta S; Pollok RC; Raine T; Smith PJ; Verma AM; Jochum S; McDonald TJ; Sebastian S; Lees CW; Powell N; Ahmad T;
    Gut; 2021 Oct; 70(10):1884-1893. PubMed ID: 33903149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
    Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD
    Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
    Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N;
    Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine Acceptance in Patients with Inflammatory Bowel Disease: Lessons Learned from the COVID-19 Pandemic.
    Mastrangeli G; Vernia F; Necozione S; Muselli M; Frassino S; Cesaro N; Latella G; Fabiani L
    Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
    Alexander JL; Mullish BH; Danckert NP; Liu Z; Olbei ML; Saifuddin A; Torkizadeh M; Ibraheim H; Blanco JM; Roberts LA; Bewshea CM; Nice R; Lin S; Prabhudev H; Sands C; Horneffer-van der Sluis V; Lewis M; Sebastian S; Lees CW; Teare JP; Hart A; Goodhand JR; Kennedy NA; Korcsmaros T; Marchesi JR; Ahmad T; Powell N
    EBioMedicine; 2023 Feb; 88():104430. PubMed ID: 36634565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 Vaccine Hesitancy in Patients with Inflammatory Bowel Disease.
    Clarke K; Pelton M; Stuart A; Tinsley A; Dalessio S; Bernasko N; Williams ED; Coates M
    Dig Dis Sci; 2022 Oct; 67(10):4671-4677. PubMed ID: 35092534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
    Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
    Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of anti-SARS-CoV-2 BNT162b2 mRNA vaccination on thrombin generation in children with inflammatory bowel disease.
    Stercel V; Lóczi L; Kadenczki O; Nemes É; Nagy B; Hodossy-Takács R; Szabó AÁ; Fagyas M; Kappelmayer J; Szabó T; Bagoly Z
    Front Immunol; 2023; 14():1257072. PubMed ID: 37965328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.
    Alexander JL; Kennedy NA; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Liu Z; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Boyton RJ; Goodhand JR; Hart AL; Lees CW; Ahmad T; Powell N;
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):342-352. PubMed ID: 35123676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B vaccination in patients with inflammatory bowel disease.
    Ben Musa R; Gampa A; Basu S; Keshavarzian A; Swanson G; Brown M; Abraham R; Bruninga K; Losurdo J; DeMeo M; Mobarhan S; Shapiro D; Mutlu E
    World J Gastroenterol; 2014 Nov; 20(41):15358-66. PubMed ID: 25386085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in Coronavirus disease - 19 vaccination related side effects in patients with ulcerative colitis and Crohn's disease in Japan.
    Miyazaki H; Watanabe D; Ito Y; Ikeda S; Okamoto N; Tokunaga E; Ku Y; Ooi M; Hoshi N; Kodama Y
    Indian J Gastroenterol; 2023 Oct; 42(5):701-707. PubMed ID: 37505394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with inflammatory bowel disease are more hesitant about Coronavirus disease 2019 vaccination.
    Kwon HJ; Panagos K; Alizadeh M; Bell M; Bourmaf M; Zisman E; Paul P; Sibel L; Wong U
    Front Med (Lausanne); 2022; 9():1005121. PubMed ID: 36457565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delay in prior authorization of biologic therapy: Another possible cause of healthcare disparity in IBD patients.
    Rao V; Dharia I; Gibilisco J; Kirelik D; Baumgartner S; Negreira K; Chawla K; Dave J; Kallus S; Belfaqeeh OA; Borum ML
    J Natl Med Assoc; 2024 Feb; 116(1):13-15. PubMed ID: 38036315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease.
    Haar GS; Vasudevan A; Curtain CM; van Langenberg DR
    Res Social Adm Pharm; 2021 Aug; 17(8):1420-1425. PubMed ID: 33129684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy: Fearless and with desire.
    Ramos L; Carrillo-Palau M; Alonso-Abreu I; Reygosa C; Hernández-Alvarez N; Amaral C; Hernández A; Benítez-Zafra F; Pérez-González F; Quintana-Díaz H; Hernandez-Guerra M
    Gastroenterol Hepatol; 2023 Apr; 46(4):255-260. PubMed ID: 35609791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients.
    Andrade P; Santos-Antunes J; Rodrigues S; Lopes S; Macedo G
    J Gastroenterol Hepatol; 2015 Nov; 30(11):1591-5. PubMed ID: 25967740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.